Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 Ballot 3 World

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example ResearchStudy: Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

Page standards status: Informative

version: 3; Last updated: 2026-08-13 13:49:10+0000

Profile: StudyRegistryRecord

ArtifactPublicationStatus: Active

Artifact Author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:

url: https://fevir.net/resources/ResearchStudy/583768

identifier: FEvIR Object Identifier/583768, ClinicalTrials.gov/NCT05327010 (use: official), NCI-2022-02915, Registry Identifier/NCI-2022-02915, NCI10486, Other Identifier/10486, Other Identifier/10486, U.S. NIH Grant/Contract/UM1CA186688, FEvIR Linking Identifier/NCT05327010 FHIR Transform

name: NCT05327010_FHIR_Transform

title: Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

Labels

-TypeValue
*Scientific titlePhase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients With Molecularly-Selected Solid Tumors (ComBET)

citeAs:

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial [Database Entry: FHIR ResearchStudy Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 583768. Revised 2026-08-13. Available at: https://fevir.net/resources/ResearchStudy/583768. Computable resource at: https://fevir.net/resources/ResearchStudy/583768#json.

relatesTo

type: Transforms

target: https://clinicaltrials.gov/api/v2/studies/NCT05327010?format=json

relatesTo

type: Transformed With

target: https://fevir.net/ctgovconvert

relatesTo

type: Supported With

target: https://reporter.nih.gov/quickSearch/UM1CA186688

relatesTo

type: Supported With

target: https://grants.nih.gov/policy/sharing.htm

status: Active

purposeType: Treatment Study

phase: Phase 2

studyDesign: Design Masking: None (Open Label), Design Allocation: NA, Uncontrolled cohort design, interventional research

condition: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm

descriptionSummary:

This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely to be cured or controlled with treatment and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Another aim of this study is to find out if, and how, patients' genes influence their response to this specific drug combination. For this part of the study, investigators will run tests using samples of patients' tumor tissue and blood that will be collected during the study. ZEN-3694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that overproduce BET protein. Talazoparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Genes are pieces of the DNA code that individuals inherit from their parents. Some genes work to protect against cancer by correcting damage that can occur in the DNA when cells divide. BRCA1 and BRCA2 are two examples of these types of genes, and they are called tumor-suppressor genes. For example, if a person has a mutation in a BRCA1/2 gene they have a greatly increased risk of developing breast and ovarian cancer because their cells may no longer be able to completely repair damaged DNA. It is the accumulation of DNA damage which causes a cell to change into a cancerous cell. Other genes are also involved in this process, and these are called DNA damage repair genes. The KRAS mutation is a change in a protein in normal cells. Normally KRAS serves as an information hub for signals in the cell that lead to cell growth, but when there is a mutation in KRAS it signals too much and cells grow without being told to, which causes cancer. Combination therapy with ZEN-3694 and talazoparib may be effective at slowing or stopping tumor growth in patients with advanced cancer.

description:

PRIMARY OBJECTIVE:

I. To evaluate clinical response to the combination of BET bromodomain inhibitor ZEN-3694 (ZEN003694 [ZEN-3694]) and talazoparib using objective response rate (ORR) = (complete response [CR] + partial response [PR]).

SECONDARY OBJECTIVES:

I. To confirm the safety and toxicity profile of the combination of ZEN003694 (ZEN-3694) and talazoparib.

II. To evaluate the clinical benefit rate (stable disease [SD] > 6 months [m]+CR+PR) and progression-free survival (PFS).

III. To assess the pharmacodynamics of the combination of ZEN003694 (ZEN-3694) and talazoparib using pre- and on-treatment tumor biopsies.

IV. To characterize pharmacodynamic changes of exploratory biomarkers to the combination of ZEN003694 (ZEN-3694) and talazoparib in pre- and on-treatment tumor biopsies.

V. To assess putative predictive biomarkers of response and resistance to the combination of ZEN003694 (ZEN-3694) and talazoparib.

OUTLINE:

Patients receive ZEN-3694 orally (PO) once daily (QD) and talazoparib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo diagnostic imaging, blood sample collection, and tumor biopsy throughout the study.

After completion of study treatment, patients are followed up 30 days after administration of the last dose of study drug and then every 3 months for up to 2 years.

site:

classifier: IPDSharing: Yes, IPDSharingDescription: NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page., Does not include healthy volunteers, Includes female subjects, Includes male subjects, Minimum Age: 18 Years, Age Group: Adult, Age Group: Older Adult, Has Results: False, Oversight Classifier: oversightHasDmc False, Oversight Classifier: isFdaRegulatedDrug True, Oversight Classifier: isFdaRegulatedDevice False

associatedParty

name: National Cancer Institute (NCI)

role: Sponsor

classifier: NIH

associatedParty

name: National Cancer Institute (NCI)

role: Lead sponsor

classifier: NIH

associatedParty

name: Timothy A Yap

role: Principal investigator

party: University of Texas MD Anderson Cancer Center LAO

progressStatus

state: Recruiting

progressStatus

state: Registration submission

actual: true

period: 2022-04-13 --> (ongoing)

progressStatus

state: Registration submission Quality Check

actual: true

period: 2022-04-13 --> (ongoing)

progressStatus

state: Record Verification

actual: true

period: ?? --> 2026-07

progressStatus

state: Update submission

actual: true

period: ?? --> 2026-07-17

progressStatus

state: Registration posting

actual: true

period: 2022-04-14 --> (ongoing)

progressStatus

state: Primary outcome data collection

actual: false

period: ?? --> 2026-12-31

progressStatus

state: Update posting

actual: true

period: ?? --> 2026-07-20

progressStatus

state: Overall study

actual: true

period: 2022-11-14 --> (ongoing)

progressStatus

state: Overall study

actual: false

period: ?? --> 2027-12-31

Recruitments

-TargetNumberEligibility
*88NCT05327010 Eligibility Criteria

ComparisonGroups

-EligibilityNameDescription
*​Treatment (ZEN-3694, talazoparib)Treatment (ZEN-3694, talazoparib)

Patients receive ZEN-3694 PO QD and talazoparib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo diagnostic imaging, blood sample collection, and tumor biopsy throughout the study.

objective

type: Primary

OutcomeMeasures

-NameTypeDescriptionEndpoint
*Objective response rate (ORR)Primary

Systemically assessed per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. ORR = complete response + partial response. Complete response is defined as the disappearance of all target or non-target lesions. Partial response is defined as at least a 30% decrease in the sum of the diameters of target or non-target lesions.

Objective response rate (ORR)

objective

type: Secondary

outcomeMeasure

name: Duration of response

type: Secondary

description:

Assessed using RECIST v1.1.

endpoint: Duration of response

outcomeMeasure

name: Clinical benefit rate (CBR)

type: Secondary

description:

Assessed by radiographic disease assessments per RECIST v1.1. CBR = overall response + stable disease > 6 months. Stable disease is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.

endpoint: Clinical benefit rate (CBR)

outcomeMeasure

name: Progression-free survival

type: Secondary

description:

Assessed by radiographic disease assessments per RECIST v1.1.

endpoint: Progression-free survival

outcomeMeasure

name: Overall survival

type: Secondary

description:

Assessed by radiographic disease assessments per RECIST v1.1.

endpoint: Overall survival

outcomeMeasure

name: Incidence of adverse events

type: Secondary

description:

Incidence and severity of adverse events and serious adverse events as graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Includes significant changes in laboratory parameters, electrocardiograms, and vital signs. Summarized by grade and type.

endpoint: Incidence of adverse events

objective

type: Exploratory

outcomeMeasure

name: Treatment-induced changes in phospho-protein signaling

type: Exploratory

description:

Reverse phase proteomic array in pre- and on-treatment tumor biopsy samples conducted to assess treatment-induced changes in phospho-protein signaling, to correlate with treatment response and progression, and to assess changes in the levels of cytotoxic T lymphocyte precursor.

endpoint: Treatment-induced changes in phospho-protein signaling

outcomeMeasure

name: Correlation of single nucleotide variant (SNV) and copy number variant (CNV) profiles with treatment response

type: Exploratory

description:

Whole exome sequencing conducted on pre-treatment biopsy and at progression to correlate SNV and CNV profiles with treatment response.

endpoint: Correlation of single nucleotide variant (SNV) and copy number variant (CNV) profiles with treatment response

outcomeMeasure

name: Gene expression profiling

type: Exploratory

description:

Ribonucleic acid (RNA) sequencing conducted for gene expression profiling.

endpoint: Gene expression profiling

outcomeMeasure

name: Correlate mutation profiles with tumor sequencing

type: Exploratory

description:

Using circulating tumor deoxyribonucleic acid (ctDNA) for correlation.

endpoint: Correlate mutation profiles with tumor sequencing

outcomeMeasure

name: Correlate baseline mutations with treatment response

type: Exploratory

description:

Using ctDNA for correlation.

endpoint: Correlate baseline mutations with treatment response

outcomeMeasure

name: Correlate changes in ctDNA variant allele frequencies with response

type: Exploratory

description:

Using ctDNA for correlation.

endpoint: Correlate changes in ctDNA variant allele frequencies with response

outcomeMeasure

name: Assess emergent resistant mutations

type: Exploratory

description:

Includes BRCA reversion.

endpoint: Assess emergent resistant mutations

outcomeMeasure

name: Analysis of formalin-fixed paraffin-embedded and blood and blood samples

type: Exploratory

description:

DNA, RNA, and protein analysis conducted.

endpoint: Analysis of formalin-fixed paraffin-embedded and blood and blood samples

Generated Narrative: EvidenceVariable #NCT05327010-drug------bet-bromodomain-inhibitor-zen-3694

name: NCT05327010_drug______bet_bromodomain_inhibitor_zen_3694

title: BET Bromodomain Inhibitor ZEN-3694

status: Active

description:

Given PO

note: , , ,

suggested alternative name: BETi ZEN-3694

suggested alternative name: ZEN 3694

suggested alternative name: ZEN-3694

suggested alternative name: ZEN003694

handling: boolean variable

classifier: Intervention Type: DRUG

Generated Narrative: EvidenceVariable #NCT05327010-procedure------biopsy-procedure

name: NCT05327010_procedure______biopsy_procedure

title: Biopsy Procedure

status: Active

description:

Undergo tumor biopsy

note: , ,

suggested alternative name: Biopsy

suggested alternative name: BIOPSY_TYPE

suggested alternative name: Bx

handling: boolean variable

classifier: Intervention Type: PROCEDURE

Generated Narrative: EvidenceVariable #NCT05327010-procedure------biospecimen-collection

name: NCT05327010_procedure______biospecimen_collection

title: Biospecimen Collection

status: Active

description:

Undergo blood sample collection

note: , , ,

suggested alternative name: Biological Sample Collection

suggested alternative name: Biospecimen Collected

suggested alternative name: Sample Collection

suggested alternative name: Specimen Collection

handling: boolean variable

classifier: Intervention Type: PROCEDURE

Generated Narrative: EvidenceVariable #NCT05327010-procedure------diagnostic-imaging-testing

name: NCT05327010_procedure______diagnostic_imaging_testing

title: Diagnostic Imaging Testing

status: Active

description:

Undergo diagnostic imaging

note: ,

suggested alternative name: Diagnostic Imaging

suggested alternative name: Medical Imaging

handling: boolean variable

classifier: Intervention Type: PROCEDURE

Generated Narrative: EvidenceVariable #NCT05327010-drug------talazoparib

name: NCT05327010_drug______talazoparib

title: Talazoparib

status: Active

description:

Given PO

note: , ,

suggested alternative name: BMN 673

suggested alternative name: BMN-673

suggested alternative name: BMN673

handling: boolean variable

classifier: Intervention Type: DRUG

Exception parsing generated Narrative (see /tmp/liquid-abd29a78-3adc-4bd0-98a3-55438a30a85b.html): Error in template: Root element is not 'div'

Generated Narrative: ResearchStudy #NCT05327010-Location-0-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: City of Hope Comprehensive Cancer Center

ProgressStatuses

-State
*Recruiting

Generated Narrative: Location #NCT05327010-Location-0

City of Hope Comprehensive Cancer Center

Address:Duarte California 91010 United States
Position:34.13945, -117.97729
General contact:
Principal investigator:
  • Irene M. Kang

Generated Narrative: ResearchStudy #NCT05327010-Location-1-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: City of Hope at Irvine Lennar

ProgressStatuses

-State
*Recruiting

Generated Narrative: Location #NCT05327010-Location-1

City of Hope at Irvine Lennar

Address:Irvine California 92618 United States
Position:33.66946, -117.82311
General contact:
  • Site Public Contact
  • ph: 877-467-3411
Principal investigator:
  • Irene M. Kang

Generated Narrative: ResearchStudy #NCT05327010-Location-2-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: UC San Diego Moores Cancer Center

ProgressStatuses

-State
*Recruiting

Generated Narrative: Location #NCT05327010-Location-2

UC San Diego Moores Cancer Center

Address:La Jolla California 92093 United States
Position:32.84727, -117.2742
General contact:
Principal investigator:
  • Rana R. McKay

Generated Narrative: ResearchStudy #NCT05327010-Location-3-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: Keck Medicine of USC Koreatown

ProgressStatuses

-State
*Active, not recruiting

Generated Narrative: Location #NCT05327010-Location-3

Keck Medicine of USC Koreatown

Address:Los Angeles California 90020 United States
Position:34.05223, -118.24368

Generated Narrative: ResearchStudy #NCT05327010-Location-4-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: Los Angeles General Medical Center

ProgressStatuses

-State
*Active, not recruiting

Generated Narrative: Location #NCT05327010-Location-4

Los Angeles General Medical Center

Address:Los Angeles California 90033 United States
Position:34.05223, -118.24368

Generated Narrative: ResearchStudy #NCT05327010-Location-5-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: USC / Norris Comprehensive Cancer Center

ProgressStatuses

-State
*Active, not recruiting

Generated Narrative: Location #NCT05327010-Location-5

USC / Norris Comprehensive Cancer Center

Address:Los Angeles California 90033 United States
Position:34.05223, -118.24368

Generated Narrative: ResearchStudy #NCT05327010-Location-6-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: USC Norris Oncology/Hematology-Newport Beach

ProgressStatuses

-State
*Active, not recruiting

Generated Narrative: Location #NCT05327010-Location-6

USC Norris Oncology/Hematology-Newport Beach

Address:Newport Beach California 92663 United States
Position:33.61891, -117.92895

Generated Narrative: ResearchStudy #NCT05327010-Location-7-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: University of California Davis Comprehensive Cancer Center

ProgressStatuses

-State
*Active, not recruiting

Generated Narrative: Location #NCT05327010-Location-7

University of California Davis Comprehensive Cancer Center

Address:Sacramento California 95817 United States
Position:38.58157, -121.4944

Generated Narrative: ResearchStudy #NCT05327010-Location-8-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: UC San Diego Medical Center - Hillcrest

ProgressStatuses

-State
*Recruiting

Generated Narrative: Location #NCT05327010-Location-8

UC San Diego Medical Center - Hillcrest

Address:San Diego California 92103 United States
Position:32.71571, -117.16472
General contact:
Principal investigator:
  • Rana R. McKay

Generated Narrative: ResearchStudy #NCT05327010-Location-9-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: UCHealth University of Colorado Hospital

ProgressStatuses

-State
*Active, not recruiting

Generated Narrative: Location #NCT05327010-Location-9

UCHealth University of Colorado Hospital

Address:Aurora Colorado 80045 United States
Position:39.72943, -104.83192

Generated Narrative: ResearchStudy #NCT05327010-Location-10-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: Yale University

ProgressStatuses

-State
*Active, not recruiting

Generated Narrative: Location #NCT05327010-Location-10

Yale University

Address:New Haven Connecticut 06520 United States
Position:41.30815, -72.92816

Generated Narrative: ResearchStudy #NCT05327010-Location-11-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: Smilow Cancer Hospital Care Center-Trumbull

ProgressStatuses

-State
*Active, not recruiting

Generated Narrative: Location #NCT05327010-Location-11

Smilow Cancer Hospital Care Center-Trumbull

Address:Trumbull Connecticut 06611 United States
Position:41.24287, -73.20067

Generated Narrative: ResearchStudy #NCT05327010-Location-12-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: UF Health Cancer Institute - Gainesville

ProgressStatuses

-State
*Active, not recruiting

Generated Narrative: Location #NCT05327010-Location-12

UF Health Cancer Institute - Gainesville

Address:Gainesville Florida 32610 United States
Position:29.65163, -82.32483

Generated Narrative: ResearchStudy #NCT05327010-Location-13-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: Emory University Hospital/Winship Cancer Institute

ProgressStatuses

-State
*Recruiting

Generated Narrative: Location #NCT05327010-Location-13

Emory University Hospital/Winship Cancer Institute

Address:Atlanta Georgia 30322 United States
Position:33.749, -84.38798
General contact:
  • Site Public Contact
  • ph: 404-778-1868
Principal investigator:
  • Ticiana A. Leal

Generated Narrative: ResearchStudy #NCT05327010-Location-14-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: Northwestern University

ProgressStatuses

-State
*Recruiting

Generated Narrative: Location #NCT05327010-Location-14

Northwestern University

Address:Chicago Illinois 60611 United States
Position:41.85003, -87.65005
General contact:
Principal investigator:
  • Aparna Kalyan

Generated Narrative: ResearchStudy #NCT05327010-Location-15-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: University of Kansas Clinical Research Center

ProgressStatuses

-State
*Recruiting

Generated Narrative: Location #NCT05327010-Location-15

University of Kansas Clinical Research Center

Address:Fairway Kansas 66205 United States
Position:39.02223, -94.6319
General contact:
Principal investigator:
  • Joaquina C. Baranda

Generated Narrative: ResearchStudy #NCT05327010-Location-16-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: University of Kansas Cancer Center

ProgressStatuses

-State
*Recruiting

Generated Narrative: Location #NCT05327010-Location-16

University of Kansas Cancer Center

Address:Kansas City Kansas 66160 United States
Position:39.11417, -94.62746
General contact:
Principal investigator:
  • Joaquina C. Baranda

Generated Narrative: ResearchStudy #NCT05327010-Location-17-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: University of Kansas Cancer Center-Overland Park

ProgressStatuses

-State
*Recruiting

Generated Narrative: Location #NCT05327010-Location-17

University of Kansas Cancer Center-Overland Park

Address:Overland Park Kansas 66210 United States
Position:38.98223, -94.67079
General contact:
Principal investigator:
  • Joaquina C. Baranda

Generated Narrative: ResearchStudy #NCT05327010-Location-18-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: University of Kansas Hospital-Indian Creek Campus

ProgressStatuses

-State
*Recruiting

Generated Narrative: Location #NCT05327010-Location-18

University of Kansas Hospital-Indian Creek Campus

Address:Overland Park Kansas 66211 United States
Position:38.98223, -94.67079
General contact:
Principal investigator:
  • Joaquina C. Baranda

Generated Narrative: ResearchStudy #NCT05327010-Location-19-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: University of Kansas Hospital-Westwood Cancer Center

ProgressStatuses

-State
*Recruiting

Generated Narrative: Location #NCT05327010-Location-19

University of Kansas Hospital-Westwood Cancer Center

Address:Westwood Kansas 66205 United States
Position:39.04056, -94.6169
General contact:
Principal investigator:
  • Joaquina C. Baranda

Generated Narrative: ResearchStudy #NCT05327010-Location-20-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: University of Kentucky/Markey Cancer Center

ProgressStatuses

-State
*Recruiting

Generated Narrative: Location #NCT05327010-Location-20

University of Kentucky/Markey Cancer Center

Address:Lexington Kentucky 40536 United States
Position:37.98869, -84.47772
General contact:
  • Site Public Contact
  • ph: 859-257-3379
Principal investigator:
  • Rachel W. Miller

Generated Narrative: ResearchStudy #NCT05327010-Location-21-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: Ochsner Medical Center Jefferson

ProgressStatuses

-State
*Recruiting

Generated Narrative: Location #NCT05327010-Location-21

Ochsner Medical Center Jefferson

Address:New Orleans Louisiana 70121 United States
Position:29.95465, -90.07507
General contact:
Principal investigator:
  • Daniel Johnson

Generated Narrative: ResearchStudy #NCT05327010-Location-22-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: National Cancer Institute Developmental Therapeutics Clinic

ProgressStatuses

-State
*Recruiting

Generated Narrative: Location #NCT05327010-Location-22

National Cancer Institute Developmental Therapeutics Clinic

Address:Bethesda Maryland 20892 United States
Position:38.98067, -77.10026
General contact:
  • Site Public Contact
  • ph: 800-411-1222
Principal investigator:
  • A P. Chen

Generated Narrative: ResearchStudy #NCT05327010-Location-23-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: National Institutes of Health Clinical Center

ProgressStatuses

-State
*Active, not recruiting

Generated Narrative: Location #NCT05327010-Location-23

National Institutes of Health Clinical Center

Address:Bethesda Maryland 20892 United States
Position:38.98067, -77.10026

Generated Narrative: ResearchStudy #NCT05327010-Location-24-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: University of Kansas Cancer Center - North

ProgressStatuses

-State
*Recruiting

Generated Narrative: Location #NCT05327010-Location-24

University of Kansas Cancer Center - North

Address:Kansas City Missouri 64154 United States
Position:39.09973, -94.57857
General contact:
Principal investigator:
  • Joaquina C. Baranda

Generated Narrative: ResearchStudy #NCT05327010-Location-25-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: University of Kansas Cancer Center - Lee's Summit

ProgressStatuses

-State
*Recruiting

Generated Narrative: Location #NCT05327010-Location-25

University of Kansas Cancer Center - Lee's Summit

Address:Lee's Summit Missouri 64064 United States
Position:38.91084, -94.38217
General contact:
Principal investigator:
  • Joaquina C. Baranda

Generated Narrative: ResearchStudy #NCT05327010-Location-26-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: University of Kansas Cancer Center at North Kansas City Hospital

ProgressStatuses

-State
*Temporarily Closed to Accrual

Generated Narrative: Location #NCT05327010-Location-26

University of Kansas Cancer Center at North Kansas City Hospital

Address:North Kansas City Missouri 64116 United States
Position:39.13, -94.56218

Generated Narrative: ResearchStudy #NCT05327010-Location-27-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: UNC Lineberger Comprehensive Cancer Center

ProgressStatuses

-State
*Recruiting

Generated Narrative: Location #NCT05327010-Location-27

UNC Lineberger Comprehensive Cancer Center

Address:Chapel Hill North Carolina 27599 United States
Position:35.9132, -79.05584
General contact:
Principal investigator:
  • Shetal Patel

Generated Narrative: ResearchStudy #NCT05327010-Location-28-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: University of Pittsburgh Cancer Institute (UPCI)

ProgressStatuses

-State
*Recruiting

Generated Narrative: Location #NCT05327010-Location-28

University of Pittsburgh Cancer Institute (UPCI)

Address:Pittsburgh Pennsylvania 15232 United States
Position:40.44062, -79.99589
General contact:
  • Site Public Contact
  • ph: 412-647-8073
Principal investigator:
  • Leonard J. Appleman

Generated Narrative: ResearchStudy #NCT05327010-Location-29-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: University of Texas at Austin

ProgressStatuses

-State
*Active, not recruiting

Generated Narrative: Location #NCT05327010-Location-29

University of Texas at Austin

Address:Austin Texas 78712 United States
Position:30.26715, -97.74306

Generated Narrative: ResearchStudy #NCT05327010-Location-30-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: University of Texas Medical Branch

ProgressStatuses

-State
*Recruiting

Generated Narrative: Location #NCT05327010-Location-30

University of Texas Medical Branch

Address:Galveston Texas 77555-0565 United States
Position:29.30135, -94.7977
General contact:
Principal investigator:
  • Maurice Willis

Generated Narrative: ResearchStudy #NCT05327010-Location-31-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: UT MD Anderson Cancer Center

ProgressStatuses

-State
*Recruiting

Generated Narrative: Location #NCT05327010-Location-31

UT MD Anderson Cancer Center

Address:Houston Texas 77030 United States
Position:29.76328, -95.36327
General contact:
Principal investigator:
  • Timothy A. Yap

Generated Narrative: ResearchStudy #NCT05327010-Location-32-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: University of Texas Health Science Center at San Antonio

ProgressStatuses

-State
*Recruiting

Generated Narrative: Location #NCT05327010-Location-32

University of Texas Health Science Center at San Antonio

Address:San Antonio Texas 78229 United States
Position:29.42412, -98.49363
General contact:
Principal investigator:
  • John Sarantopoulos

Generated Narrative: ResearchStudy #NCT05327010-Location-33-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: Huntsman Cancer Institute/University of Utah

ProgressStatuses

-State
*Active, not recruiting

Generated Narrative: Location #NCT05327010-Location-33

Huntsman Cancer Institute/University of Utah

Address:Salt Lake City Utah 84112 United States
Position:40.76078, -111.89105

Generated Narrative: ResearchStudy #NCT05327010-Location-34-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: University of Virginia Cancer Center

ProgressStatuses

-State
*Recruiting

Generated Narrative: Location #NCT05327010-Location-34

University of Virginia Cancer Center

Address:Charlottesville Virginia 22908 United States
Position:38.02931, -78.47668
General contact:
Principal investigator:
  • Linda R. Duska

Generated Narrative: ResearchStudy #NCT05327010-Location-35-ResearchStudy

partOf: ResearchStudy Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

status: Active

site: VCU Massey Comprehensive Cancer Center

ProgressStatuses

-State
*Recruiting

Generated Narrative: Location #NCT05327010-Location-35

VCU Massey Comprehensive Cancer Center

Address:Richmond Virginia 23298 United States
Position:37.55376, -77.46026
General contact:
Principal investigator:
  • Emily N. Kinsey